Metabolic Disorders
Research activity includes type 2 diabetes, with a focus on treatment strategies for adults requiring improved glycaemic control and optimisation of incretin-based therapies.
- HbA1c management
- GLP-1 receptor agonist therapy
- Dual incretin treatment
The diabetes portfolio reflects interest in therapies that support sustained metabolic control in people transitioning between established antidiabetic treatments.
Oncology
Clinical research also covers prostate cancer, particularly high-risk metastatic hormone-sensitive prostate cancer and disease that remains responsive to hormonal treatment.
- Androgen receptor-directed treatment
- Hormone-sensitive metastatic disease
- Radiographic progression-free survival
This oncology work is centred on treatment combinations used in advanced genitourinary cancer and settings where disease control is linked to hormonal pathways.
Combination Therapy Development
The sponsor funds research exploring how pairing established agents with newer therapies can improve outcomes in both metabolic disease and oncology.
- Therapeutic switching
- Combination regimens
- Adjunctive treatment strategies
These studies reflect interest in treatment pathways that extend beyond single-agent use, including approaches designed to refine disease control in chronic and progressive conditions.
